BeiGene | Phase 1 First-in-Human Study of BGB-C354 Alone and in Combination With Tislelizumab in Participants With Advanced Solid Tumors

A First-in-Human Study of BGB-C354 Alone and in Combination With Tislelizumab in Participants With Advanced Solid Tumors

Beigene Study ID

BGB-C354-101

ClinicalTrials.gov ID

NCT06422520

EudraCT Number

2024-513280-11-00

Sex: All

Age: 18 Years / N/A

No Study Documents

Locations

Sex: All

Age: 18 Years / N/A

No Study Documents